Liva Nova Inspire 6F (integrated arterial filter)
Elective CABG patient with standard medical history & no known coagulation pathologies. Full systemic anticoagulation was achieved & confirmed pre-CPB with an ACT over 450 seconds.
Immediately following the onset of bypass, the arterial filter was observed to have turbulent flow & higher than expected RPM's for the generated flows. The blood flow in the filter appeared to be turbulent and there was a gelatinous like appearance in the arterial line filter.
Visually all looked fine and arterial blood looked oxygenated. ACT, arterial & venous blood gases were sent immediately & indicated that there no issues with oxygenation & CO2 removal.
There was no signs of this material elsewhere within the circuit. Arterial line pressures were also noted not to be higher than expected. The decision was taken not to replace the oxygenator and continue with CPB as there was no clinical indication for changing the oxygenator.
ACT's & blood gases were repeated frequently throughout the case with no signs of impairment of function. Towards the end of the bypass run the turbulent flow appeared to resolve & the RPM's also decreased. The oxygenator was flushed through at the end of the case & there was significant residue biological in nature in the filter.
A total of 11 oxygenators were observed to have this occurrence. It is standard practice to shine a light directly on the oxygenator during CPB and to flush through the circuit to a cell saver.
No patients had a history of Covid 19 infection. In 2 of the cases coagulation screens were sent to our in hospital haematology lab, specifically D Dimer, Fibrinogen, APTT, PT, INR & PLT’s but no unusual results were noted.
None
Liva Nova Inspire 6F
The oxygenator was retained after the case & a full incident report was sent to Liva Nova. Pictures were taken during the case & following the flush through.
This had happened previously on several occasions with no negative outcomes to the patient & were all reported to Liva Nova. A total of 3 oxygenators were returned for inspection. The manufacturer did not require further oxygenator returns.
Departmental decision was taken to send blood samples for a full coagulation screening to the hospital laboratory if it should occur again.
Manufacturer informed of the events and the oxygenator was retained for inspection.
Agreed to use 8F oxygenators going forward (update: since switching the same phenomenon has been experienced four times).
See report attached
All cases where this was experienced were CABG's and only a single patient had confirmed COVID positive status at the time of procedure.